Oncostatin M (OSM)
Assets acting on this target.
- Class
- Humanized anti-OSM monoclonal antibody
- Notes
- mechanism wave 2026-08-24 (DeepSeek draft; registry text of NCT02386436 names the target); source: https://clinicaltrials.gov/study/NCT02386436
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| GSK2330811 | GlaxoSmithKline | Oncostatin M (OSM) | Crohn's Disease | Ph 2 | GSK withdrew the Phase 2 Crohn's study NCT04151225 before enrolling any subject, recording 'Internal sponsor decision to terminate project in Crohn's disease due to potential narrow therapeutic window' (registry record opened this session). No successor Crohn's study is registered. | source ↗ |